Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.32 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.32 |
| ▸ | TK1 | P04183 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | RGS12 | O14924 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | AMPD2 | Q01433 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31285260 | 0.86 | — | — | |
| SCHEMBL14640719 | 0.82 | — | — | |
| SCHEMBL29668401 | 0.81 | TBXAS1 (0.43) | CPB2KDM4ENPC1ALDH1A1LMNA | |
| SCHEMBL27772950 | 0.78 | CPB2 (0.40) | CPB2KDM4ENPC1ALDH1A1LMNA | |
| SCHEMBL27744446 | 0.77 | CPB2 (0.39) | CPB2CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL23320277 | 0.77 | TBXAS1 (0.42) | CPB2CSNK2A2CSNK2A1KDM4ESMN1; SMN2 | |
| SCHEMBL306252 | 0.74 | — | — | |
| SCHEMBL22833573 | 0.74 | — | — | |
| SCHEMBL2535349 | 0.74 | — | — | |
| SCHEMBL584318 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11466028-B2 | Fused 1,4-oxazepines as BET protein degraders | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3512855-B1 | FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-07-27 | — | — | EP | disclosed |
| CN-110062759-B | Fused 1, 4-oxazepine as BET protein degrading agent | 密执安大学评议会 | 2022-05-24 | — | — | CN | disclosed |
| US-20210284657-A1 | FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2021-09-16 | — | — | US | disclosed |
| US-20210002289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2021-01-07 | — | — | US | disclosed |
| US-10759808-B2 | Monofunctional intermediates for ligand-dependent target protein degradation | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190119289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | MDM2, CD74, TNFSF10 | CPB2 1163/4885CSNK2A2 1032/4885CSNK2B 850/4885 |
| US-10759808-B2 | Monofunctional intermediates for ligand-dependent target protein degradation | MDM2, CD74, TNFSF10 | CPB2 1163/4885CSNK2A2 1032/4885CSNK2B 850/4885 |
| US-11466028-B2 | Fused 1,4-oxazepines as BET protein degraders | BRD4, BET1, BRD1 | CPB2 4202/4885CSNK2A2 280/4885CSNK2B 178/4885 |
| US-20210002289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | MDM2, CD74, TNFSF10 | CPB2 1163/4885CSNK2A2 1032/4885CSNK2B 850/4885 |
| US-20210284657-A1 | FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS | BRD4, BET1, BRD1 | CPB2 4202/4885CSNK2A2 280/4885CSNK2B 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.